PCM
SLDB icon

Penserra Capital Management’s Solid Biosciences SLDB Stock Holding History

Penserra Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-26
Closed – – 1123
2020
Q3 		$0 Buy
+26
New +$996 ﹤0.01% 1025

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Penserra Capital Management's SLDB Position: Q4 2020 in Review

Penserra Capital Management sold out of Solid Biosciences (SLDB) in Q4 2020, closing a stake of 26 shares.

Penserra Capital Management first reported a position in SLDB in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 75 funds tracked by Wall St. Rank hold SLDB as of Q4 2020.

  • Penserra Capital Management reported no remaining Solid Biosciences position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 26 Solid Biosciences shares in Q4 2020.
  • Penserra Capital Management first reported a position in Solid Biosciences in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Solid Biosciences position peaked at $0 in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.